ATS 2020 Advance Program

12:15 Introduction to Session D.N. Weissman, MD, ATSF, Morgantown, WV 12:18 Overview of Non-Infectious Respiratory Hazards in Health Care Settings M.A. Virji, ScD, Morgantown, WV 12:37 Occupational Respiratory Disease in Dental Personnel R.J. Nett, MD, MPH, Morgantown, WV 12:56 Hazardous Respiratory Exposures in Dental Settings B. Blackley, MS, PhD, Morgantown, WV DIVISION OF LUNG DISEASES/NHLBI L7 NEW FINDINGS FROM THE NHLBI PVDOMICS PROGRAM IN PATIENTS WITH PULMONARY HYPERTENSION 12:15 p.m. - 1:15 p.m. Target Audience Health care providers, trainees, and researchers. Objectives At the conclusion of this session, the participant will be able to: • learn about the new clinical findings in PVDOMICS patients across the WHO groups of pulmonary hypertension; • gain understanding on new clinical phenotypes clustering based on new omics findings in PH; • learn about the new hemodynamic, imaging, 6 minute walk, lung physiology findings in PVDOMICS patients with pulmonary hypertension. Pulmonary hypertension (PH) has no cure, and PH research remains a high priority for NHLBI. The current PH classification is difficult to apply clinically for precision medicine therapy. In 2014, NHLBI launched a multi-center clinical study named: Redefining Pulmonary Hypertension through Pulmonary Vascular Disease Phenomics (PVDOMICS) to conduct an observational study in PH patients. The overall goal of the PVDOMICS is to perform deep phenotyping across all PH groups and intermediate phenotypes in order to reconstruct the traditional classification and define new meaningful subclassifications. Over 1100 participants are enrolled, and the clinical and omics results from these subjects will be presented at this noon session. Chairing: L. Xiao, MD, PhD, Bethesda, MD N.S. Hill, MD, Boston, MA 12:15 PVDOMICS Study: A Real World Look at Pulmonary Vascular Disease E. Horn, MD, New York, NY 12:30 Relationship Between the Six Minute Walk and Key Clinical Physiologic and Imaging Variables Across PH Subsets Enrolled In PVDOMICS K.B. Highland, MD, Cleveland, OH 12:45 Clinical and Hemodynamic Implications of WSPH Group Overlap in Pulmonary Hypertension B. Borlaug, MD, Rochester, MN 1:00 PVDOMICS: An Initial Look at Clinical and Omics Clustering A. Hemnes, MD, ATSF, Nashville, TN DIVISION OF LUNG DISEASES/NHLBI L8 UPDATES FROM THE COPDGENE STUDY 12:15 p.m. - 1:15 p.m. Target Audience Researchers, medical trainees, those with an interest in COPD pathogenesis. Objectives At the conclusion of this session, the participant will be able to: • learn about imaging in the COPDGene study; • understand and learn subtypes identified by the COPDGene study; • learn about longitudinal follow-up in the COPDGene study. Chronic obstructive pulmonary disease (COPD), the fourth leading cause of death in the U.S. is a heterologous syndrome. The COPDGene study has ATS 2020 • Philadelphia, PA SUNDAY • MAY 17 51